Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML

Senti Biosciences presented Phase 1 data for SENTI-202 in relapsed/refractory AML showing a 50% overall response rate among 18 evaluable patients, with 42% achieving complete remission and all CRs (and 83% of responses) MRD‑negative; median duration of composite CR was 7.6 months with some responses beyond one year. The CD33/FLT3-targeting Logic Gated CAR‑NK therapy had no dose‑limiting toxicities or treatment‑related serious adverse events, was generally well tolerated with mainly hematologic AEs and transient Grade 1–2 infusion‑related pyrexia, demonstrated expected peripheral expansion and clearance, and has received FDA RMAT and Orphan Drug designations as Senti plans pivotal studies and broader indications. SNTI stock jumped about 21% pre-market to $2.89 on the news (12‑month range $1.26–$6.48), underscoring investor enthusiasm while underscoring the need for confirmatory pivotal data as the next material catalyst.

Analysis

Senti Biosciences reported Phase 1 data for SENTI-202 in relapsed/refractory AML from an open-label, multinational study that enrolled 20 patients with 18 evaluable for response; the trial produced a 50% overall response rate and a 42% complete remission rate, with 100% of CRs and 83% of all responses MRD-negative. The median duration of composite CR was 7.6 months with some responses extending beyond one year, indicating early signs of depth and potential durability but based on a small sample and limited follow-up.

Safety and mechanism data were favorable: no dose-limiting toxicities or treatment-related serious adverse events were reported, most adverse events were hematologic or transient Grade 1/2 pyrexia, and peripheral expansion with natural clearance matched expectations for allogeneic NK approaches. The FDA granted RMAT and prior Orphan Drug designation, which can accelerate regulatory interactions and supports the company’s plan to advance to pivotal studies and broaden indications into newly diagnosed AML, pediatric AML and MDS.

Market reaction was immediate and positive, with SNTI trading pre-market at $2.89, up 21.33% and a 12-month trading range of $1.26–$6.48, reflecting investor enthusiasm but also flagging typical small-cap biotech volatility. Key risks remain the small cohort size, open-label design and short median follow-up; pivotal data on durability, larger-sample safety and regulatory outcomes are the next material catalysts.

Key Decisions for Investors

• Consider a small, risk-weighted position to capture upside from RMAT designation and encouraging Phase 1 MRD-negative CRs, but limit exposure given small sample size and immature durability data
• Await results from pivotal studies or longer follow-up demonstrating sustained MRD-negative remissions and larger safety datasets before adding meaningfully to positions
• Monitor near-term catalysts closely—pivotal trial initiation, enrollment milestones, durability beyond 12 months and any emerging safety signals—and size positions with volatility in mind or use hedges to protect downside